Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3126273rdf:typepubmed:Citationlld:pubmed
pubmed-article:3126273lifeskim:mentionsumls-concept:C0006826lld:lifeskim
pubmed-article:3126273lifeskim:mentionsumls-concept:C0020268lld:lifeskim
pubmed-article:3126273lifeskim:mentionsumls-concept:C0521400lld:lifeskim
pubmed-article:3126273lifeskim:mentionsumls-concept:C0010711lld:lifeskim
pubmed-article:3126273lifeskim:mentionsumls-concept:C0025677lld:lifeskim
pubmed-article:3126273lifeskim:mentionsumls-concept:C0039871lld:lifeskim
pubmed-article:3126273lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:3126273lifeskim:mentionsumls-concept:C1314939lld:lifeskim
pubmed-article:3126273pubmed:issue4lld:pubmed
pubmed-article:3126273pubmed:dateCreated1988-4-13lld:pubmed
pubmed-article:3126273pubmed:abstractTextTwenty-three adult patients with meningeal involvement by a variety of malignancies were treated with the intra-Ommaya combination of methotrexate, hydrocortisone, cytosine arabinoside, and thio-TEPA. Whole brain irradiation was also administered to most patients who had not previously received it. Most patients demonstrated improvement of cerebrospinal fluid parameters, but only 50% of the patients experienced neurological improvement. Patients who did not receive cranial irradiation and performance status 4 patients were less likely to respond than were patients who did receive cranial irradiation as part of their treatment and patients who were performance status 0-3. Four patients developed possible and 2 patients developed probable or definite serious neurological complications. Another 4 patients developed less severe, reversible neurological toxicity. It is possible (but still uncertain) that this regimen is more toxic than other less intensive regimens, and further studies should be undertaken cautiously.lld:pubmed
pubmed-article:3126273pubmed:languageenglld:pubmed
pubmed-article:3126273pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3126273pubmed:citationSubsetIMlld:pubmed
pubmed-article:3126273pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3126273pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3126273pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3126273pubmed:statusMEDLINElld:pubmed
pubmed-article:3126273pubmed:issn0167-594Xlld:pubmed
pubmed-article:3126273pubmed:authorpubmed-author:RichardMMlld:pubmed
pubmed-article:3126273pubmed:authorpubmed-author:StewartD JDJlld:pubmed
pubmed-article:3126273pubmed:authorpubmed-author:GirardAAlld:pubmed
pubmed-article:3126273pubmed:authorpubmed-author:DrouinJJlld:pubmed
pubmed-article:3126273pubmed:authorpubmed-author:MarounJ AJAlld:pubmed
pubmed-article:3126273pubmed:authorpubmed-author:BenoitBBlld:pubmed
pubmed-article:3126273pubmed:authorpubmed-author:RussellNNlld:pubmed
pubmed-article:3126273pubmed:authorpubmed-author:HugenholtzHHlld:pubmed
pubmed-article:3126273pubmed:authorpubmed-author:HuebschLLlld:pubmed
pubmed-article:3126273pubmed:issnTypePrintlld:pubmed
pubmed-article:3126273pubmed:volume5lld:pubmed
pubmed-article:3126273pubmed:ownerNLMlld:pubmed
pubmed-article:3126273pubmed:authorsCompleteYlld:pubmed
pubmed-article:3126273pubmed:pagination315-22lld:pubmed
pubmed-article:3126273pubmed:dateRevised2006-4-24lld:pubmed
pubmed-article:3126273pubmed:meshHeadingpubmed-meshheading:3126273-...lld:pubmed
pubmed-article:3126273pubmed:meshHeadingpubmed-meshheading:3126273-...lld:pubmed
pubmed-article:3126273pubmed:meshHeadingpubmed-meshheading:3126273-...lld:pubmed
pubmed-article:3126273pubmed:meshHeadingpubmed-meshheading:3126273-...lld:pubmed
pubmed-article:3126273pubmed:meshHeadingpubmed-meshheading:3126273-...lld:pubmed
pubmed-article:3126273pubmed:meshHeadingpubmed-meshheading:3126273-...lld:pubmed
pubmed-article:3126273pubmed:meshHeadingpubmed-meshheading:3126273-...lld:pubmed
pubmed-article:3126273pubmed:meshHeadingpubmed-meshheading:3126273-...lld:pubmed
pubmed-article:3126273pubmed:meshHeadingpubmed-meshheading:3126273-...lld:pubmed
pubmed-article:3126273pubmed:meshHeadingpubmed-meshheading:3126273-...lld:pubmed
pubmed-article:3126273pubmed:meshHeadingpubmed-meshheading:3126273-...lld:pubmed
pubmed-article:3126273pubmed:meshHeadingpubmed-meshheading:3126273-...lld:pubmed
pubmed-article:3126273pubmed:year1987lld:pubmed
pubmed-article:3126273pubmed:articleTitleCombined intraommaya methotrexate, cytosine arabinoside, hydrocortisone and thio-TEPA for meningeal involvement by malignancies.lld:pubmed
pubmed-article:3126273pubmed:affiliationOttawa Regional Cancer Centre, General Hospital Division, Ontario, Canada.lld:pubmed
pubmed-article:3126273pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3126273lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3126273lld:pubmed